Strategic Course Correction For A Blockbuster Oncology Drug

Longitudinal patient history in APLD can help in accurate market assessment based on trends in patient progression, line of treatment and regimens. However, since this data has missing patients or medical and Rx claims, it cannot be used standalone for deterministic analysis. Use of advanced analytics models and triangulation of various sources of data can help generate reliable estimates of product penetration and high potential opportunities allowing tailored messaging and better targeting to physicians.

A top pharma company that had done well to grow their oncology drug to a blockbuster status was struggling with understanding and achieving its full potential. Axtria provided strategic inputs for patient-level claims data to identify patients across tumor types and line of therapies. This analysis was then combined with account-level units to arrive at the drug penetration and market potential for each tumor type.

The effort resulted in the following:

More accurate understanding of market opportunity and product penetration by tumor type, regimen and at account-level

Motivated reps with actionable information for focused targeting

Better allocation of resources based on the market opportunity

Read this illustration to know how Axtria helped the client re-haul their sales targeting strategy and enabled them to unlock their brand’s full potential.

Contact us at insights@axtria.com with any questions.